Richard Snyder, Ph.D.
Vice President, Science & Technology, Pharma Services
Florida, USA
Key roles and responsibilities
- Lead the science & technology team’s company wide initiative developing multi-generational manufacturing and analytical platforms used for the GMP production of viral vectors utilized for in vivo human gene therapies and ex vivo modified-cell based therapies
Professional highlights
- Co-founder and Chief Scientific Officer of Brammer Bio, which was acquired by Thermo Fisher Scientific in 2019
- Formerly an associate professor of molecular genetics and microbiology as well as director of biotherapeutic programs at the University of Florida, and assistant professor of pediatrics at Harvard Medical School
- Experience in viral vector industry spans over thirty-three years; previously employed by Cell Cenesys, Somatix, Merlin, and Avigen
- Engaged in the development of gene transfer vector and vaccine technology along with therapeutic applications
- Author of over seventy scientific publications and also eight U.S. patents
Education
- Post-doctoral fellow at Johns Hopkins University School of Medicine
- Doctor of Philosophy in microbiology from The State University of New York at Stony Brook
- Bachelor’s degree in biology from Washington University in St. Louis
Scientific expertise
- Virus biology
- Viral vector development
- cGMP viral vector manufacturing & analytical technologies
- Viral vector mediated gene transfer
- Development of novel viral vector-based human gene therapies
